source
- Vertex reports positive Phase 2b results for inaxaplin in APOL1-mediated kidney diseaseVertex Pharmaceuticals announced positive Phase 2b data for its kidney disease candidate inaxaplin, which targets APOL1-mediated kidney disease (AMKD). The Amplified trial enrolled two cohorts: 2…
- HHS rolls out new FDA rule to allow non-animal testing methods in drug developmentThe Department of Health and Human Services announced a new set of strategies aimed at shifting drug development away from animal testing toward human-based research methods. The FDA issued a fina…